Bifunctional Tau Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease lack effective compounds that target tau protein for degradation, leading to high clinical failure rates and an unmet need for therapeutic agents that leverage cellular machinery for protein homeostasis.
Innovation Solution
Development of bifunctional compounds that conjugate tau binding moieties with E3 ubiquitin ligase binding moieties, such as lenalidomide or thalidomide, to recruit tau protein for ubiquitination and proteasome-mediated degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Alzheimer's disease, then current standard therapies are administered, but clinical failure rates remain high and effective tau-targeting compounds are lacking
Solution Approach 1:
The patent employs PROTAC compounds as intermediary molecules that bridge tau protein and E3 ubiquitin ligases. These bifunctional compounds contain a tau-binding moiety and an E3 ligase-binding moiety connected by a linker, enabling the recruitment of E3 ligases to ubiquitinate and degrade tau protein, thereby achieving effective tau targeting without direct inhibition of pathological processes
Solution Approach 2:
The patent replaces conventional pharmacological approaches with a protein degradation mechanism. Instead of inhibiting tau accumulation through receptor modulation or enzyme inhibition, the invention utilizes the cellular proteasome system to physically degrade tau protein, substituting a mechanical degradation process for conventional biochemical inhibition strategies
2Object-affected harmful factors
If tau protein accumulation is targeted for degradation, then neurofibrillary tangle reduction is achieved, but the complexity of utilizing cellular machinery increases
Solution Approach 1:
The patent harnesses the cell's own ubiquitin-proteasome system to degrade tau protein. The PROTAC compounds activate the cell's intrinsic protein degradation machinery, allowing the cell to self-cleanse of pathological tau aggregates without requiring external intervention or complex artificial degradation systems
Solution Approach 2:
The E3 ubiquitin ligase binding moieties in the PROTAC compounds can target multiple E3 ligases (e.g., Cereblon, VHL, CHIP), providing multi-functionality. This universal approach allows a single compound class to engage different degradation pathways, increasing the robustness and adaptability of tau degradation across different cellular contexts
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively promote the degradation of tau protein, offering a potential therapeutic approach for neurological disorders like Alzheimer's disease by targeting hyperphosphorylated tau protein and reducing its aggregation.
Implementation Method 1
E3 ubiquitin ligases are proteins that, in combination with an E2 ubiquitin-conjugating enzyme, promote the attachment of ubiquitin to a lysine on a target protein via an isopeptide bond
Implementation Method 2
The ubiquitination of the protein commonly results in degradation of the target protein by the proteasome
Data Source
AI summary
Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.